StockData

Rallybio vs Exicure

RLYB and XCUR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How RLYB and XCUR compare

Rallybio is the larger company, worth 12 times as much as Exicure ($82.3M against $7.1M).

Rallybio scores higher on the StockData Score (10 against 4 for Exicure), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricRLYBXCUR
Size and price
Market cap$82.3M$7.1M
Share price$15.29$1.08
Change, 1 year199%−70.9%
Change, 5 years−85.5%−98.5%
Beta (5Y)0.01−0.98
Employees148
StockData Score
Total score10 (better)4
Valuation score2 (better)0
Growth score00
Performance score2 (better)0
Health score6 (better)4
Dividend score00
Valuation
P/E3.4×–
P/S190×–
P/B0.9× (better)7.2×
Growth
Revenue growth (TTM)−35.6%–
Profitability
Operating margin−5581%–
Net margin6177%–
Return on equity34.5% (better)−168%
Return on invested capital−718% (better)−4377%
Financial health
Debt / equity0.000.00
Current ratio28.87 (better)0.56
Altman Z-score11.42 (better)−27.36
Piotroski F-score4 (better)2
Dividends and buybacks
Buyback yield–0.00%
Shareholder yield0.00%0.00%
Ownership
Held by institutions–2.1%
Held by insiders72.6%92.6%
Insider net buying, 12 months$4.2M (better)−$11.6M
Superinvestors holding1–
Short interest, % of float2.6%10.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.